67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months, compared with 33.5% of subjects in the placebo arm
Pivotal trial met primary endpoint: lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 22.4%, exceeding the pre-specified threshold of 15%
Safety results were generally consistent with safety profile of Viaskin Peanut 250 μg observed in children with peanut allergy ages 4 years and older in prior clinical trials
High treatment compliance rate observed over trial duration, with low rate of discontinuation due to adverse events
DBV will hold a conference call today at 5:00 p.m. ET to discuss the results
DBV will host a conference call and live audio webcast on Tuesday, June 7, 2022, at 5:00 p.m. ET to discuss the results. This call is accessible via the below teleconferencing numbers, followed by the reference ID: 23143278#
United States: 866 374 5140
Canada: 866 455 3403
United Kingdom: 808 238 9813
France: 805 102 712
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
https://finance.yahoo.com/news/dbv-technologies-announces-positive-topline-203000138.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.